Gapping down
In reaction to disappointing earnings/guidance:
In reaction to disappointing earnings/guidance:
- DLR -0.5%, ( sees FY17 funds from operations of $5.90-6.10 vs $6.02 Capital IQ Consensus Estimate; FY16 $5.65-5.75 vs. $5.69 consensus)
Other news:
- AGRX -62.4% (announces 'positive' top-line results from its Phase 3 SECURE clinical trial of Twirla; plans to resubmit its NDA for Twirla in the first half of 2017 on the basis of the SECURE results)
- ACUR -10.7% (announces they are exploring a full range of financing and strategic alternatives, including a possible sale of the company)
- ARR -3% (announces January 2017 dividend rate per common share of $0.19 vs $0.22/share prior month)
- CLVS -2.7% (prices / upsizes public offering of 5 mln shares of common stock at $41/ per share)
- TSLA -1% (Misses Q4 delivery targets on production delays related to new autopilot hardware; net orders set new record)
- SFR +-0.5% (commences a private offering of $250 million aggregate principal amount of convertible senior notes due 2022)
Analyst comments:
- COG -2.2% (downgraded to Underperform at BofA/Merrill)
- STM -2.2% (downgraded to Underweight from Equal-Weight at Morgan Stanley)
- VRX -1.4% (target lowered to $11 from $16 at Piper Jaffray)
- OSK -1.2% (downgraded to Hold from Buy at Deutsche Bank)
- DNKN -1.1% (downgraded to Underperform from Hold at Jefferies )
- SWN -1.1% (downgraded to Underperform at BofA/Merrill)